Legend Biotech Holds 2024 Shareholder Meeting
Ticker: LEGN · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
TL;DR
Legend Biotech held its shareholder meeting on Oct 21, 2024. Results filed.
AI Summary
On October 21, 2024, Legend Biotech Corporation held its 2024 Annual General Meeting of Shareholders. The voting results from this meeting have been filed with the SEC as Exhibit 99.1 to this Form 6-K report.
Why It Matters
This filing provides transparency on the outcomes of shareholder votes, which can impact corporate governance and future strategic decisions for Legend Biotech.
Risk Assessment
Risk Level: low — The filing is a routine report of shareholder meeting results and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- October 21, 2024 (date) — Date of Annual General Meeting
FAQ
What type of meeting did Legend Biotech Corporation hold on October 21, 2024?
Legend Biotech Corporation held its 2024 Annual General Meeting of Shareholders on October 21, 2024.
What is being filed as Exhibit 99.1 to this Form 6-K?
The voting results from the 2024 Annual General Meeting of Shareholders are attached as Exhibit 99.1.
What is the Commission File Number for Legend Biotech Corporation?
The Commission File Number for Legend Biotech Corporation is 001-39307.
Where is Legend Biotech Corporation's principal executive office located?
Legend Biotech Corporation's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
Does Legend Biotech Corporation file annual reports under Form 20-F or Form 40-F?
Legend Biotech Corporation indicates it files annual reports under Form 20-F.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-10-21 16:03:49
Filing Documents
- d878483d6k.htm (6-K) — 9KB
- d878483dex991.htm (EX-99.1) — 18KB
- 0001193125-24-240395.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: October 21, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer